Strategic Client Base Visikol already counts all twenty of the top twenty pharmaceutical companies as clients, indicating strong enterprise demand for advanced tissue imaging and cell culture services. Sales opportunities can focus on expanding within these large pharma relationships and leveraging case studies to win new programs.

GLP and Mass Cytometry Recent launches include GLP multiplex imaging services and Imaging Mass Cytometry, offering high-value, regulated capabilities. Leverage these differentiators to target pharma R&D teams seeking compliant, scalable imaging throughput and multi-marker analysis.

BBB Expertise Visikol has expanded into blood-brain barrier (BBB) modeling and permeability assays, a niche area with strong translational value for CNS programs. Target neurodegenerative and CNS drug developers needing BBB penetration data and mechanistic insights.

3D and Tissue Models Portfolio includes 3D tissue imaging, 3D cell culture, tissue slices, and ex vivo models, enabling more predictive biology. Position these models to pharmaceutical discovery teams aiming to de-risk translational gaps and strengthen decision-making pipelines.

Strategic Partnerships Collaborations with notable imaging technology leaders and a diverse service suite present cross-sell opportunities for adjacent capabilities like high-content imaging, digital pathology, and tissue clearing. Propose bundled offerings to streamline vendor management and expand service adoption.